10 -

10 - Iveson T, Donehower R.C, Davidenko I et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncology. 2014;15(9):1007-18 [link]